Abstract
Lung transplantation is an option for appropriately selected patients with end-stage emphysema caused by alpha 1-antitrypsin deficiency. The functional results have been excellent after single or bilateral lung transplantation, and the medium-term survival results have been good. However, the role of alpha 1-antitrypsin replacement therapy after lung transplantation remains uncertain, and further investigation is needed.
MeSH terms
-
Humans
-
Lung Diseases, Obstructive / surgery
-
Lung Transplantation* / mortality
-
Lung Transplantation* / statistics & numerical data
-
Pulmonary Emphysema / mortality
-
Pulmonary Emphysema / physiopathology
-
Pulmonary Emphysema / surgery*
-
Recombinant Proteins / therapeutic use
-
Registries
-
Respiratory Function Tests
-
Survival Rate
-
United States
-
alpha 1-Antitrypsin / biosynthesis
-
alpha 1-Antitrypsin / therapeutic use
-
alpha 1-Antitrypsin Deficiency*
Substances
-
Recombinant Proteins
-
alpha 1-Antitrypsin